Home News What Experts Are Learning About Sotatercept for PAH back to News
minute read
Earlier this week, new phase 2 data showed investigative therapy sotatercept was beneficial in improving pulmonary vascular resistance and six-minute walking test (6MWT) outcomes in patients with pulmonary arterial hypertension (PAH) at 24 weeks.
Topics: Press Coverage
13001 East 17th Place
Aurora, CO 80045
303.724.5375
© 2024 The Regents of the University of Colorado, a body corporate. All rights reserved.
Accredited by the Higher Learning Commission. All trademarks are registered property of the University. Used by permission only.
